This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

BioNTech files CureVac acquisition for German approval

By Jean Comte ( September 22, 2025, 16:26 GMT | Insight) -- German biotechnology company BioNTech has filed its intended acquisition of mRNA treatment designer CureVac for approval in Germany. The national competition authority has one month to decide on the deal. The deal was also filed for EU approval under foreign subsidies rules earlier this month.German biotechnology company BioNTech filed its intended acquisition of mRNA treatment designer CureVac for approval in Germany last week, according to a Monday update on the national competition authority's register of deals....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login